Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113834
Chunk: 44

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 44
---
, 2025;

our Current Reports on Form 8-K filed with the SEC on February 20, 2025 , April 29, 2025 , May 6, 2025 (Items 8.01 and 9.01), June 18, 2025 , August 8, 2025 , August 12, 2025 (Item 1.01) and August 12, 2025 (Items 1.01, 5.03, 8.01 and 9.01), August 15, 2025 , and August 28, 2025 ;

the description of the Company’s Common Stock contained in Amendment No. 3 to that certain registration statement on Form 8-A , filed with the SEC on July 6, 2017 pursuant to Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating that description;

the description of the Company’s Series B Preferred Stock contained in the registration statement on Form 8-A , filed with the SEC on August 15, 2025 pursuant to Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating that description; and

any statement contained in any document incorporated by reference herein will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any additional prospectus supplements modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with this prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. To request such materials, please contact Ira Duarte, Executive Vice President, Chief Financial Officer at the following address or telephone number: Heron Therapeutics, Inc., 100 Regency Forest Drive, Suite 300, Cary, North Carolina 27518, (858) 251-4400. A copy of all documents that are incorporated by reference into this prospectus can also be found on our website by accessing www.herontx.com.

<div align='center'>32

LEGALMATTERS</div>

The